Literature DB >> 2156383

Clinical pharmacokinetics of daptomycin.

R D Pryka1, R M Novak, D K Wagner, K A Rodvold.   

Abstract

Daptomycin is a new lipopeptide antibiotic for which preliminary pharmacokinetic data in adults have been limited to normal healthy volunteers and patients with renal insufficiency. We report the clinical pharmacokinetics of the first and fifth doses of iv daptomycin 150 mg (2 mg/kg) q24h in a 29-year-old man being treated for a gram-positive cellulitis and thrombophlebitis. Individual pharmacokinetic parameters yielded similar results during doses one and five. The pharmacokinetic profile observed in our patient did not markedly differ from data obtained from healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156383     DOI: 10.1177/106002809002400309

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  5 in total

Review 1.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

2.  Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers.

Authors:  J R Woodworth; E H Nyhart; G L Brier; J D Wolny; H R Black
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens.

Authors:  Andres Beiras-Fernandez; Ferdinand Vogt; Ralf Sodian; Florian Weis
Journal:  Infect Drug Resist       Date:  2010-08-30       Impact factor: 4.003

4.  Overexpression and purification of U24 from human herpesvirus type-6 in E. coli: unconventional use of oxidizing environments with a maltose binding protein-hexahistine dual tag to enhance membrane protein yield.

Authors:  Andrew R Tait; Suzana K Straus
Journal:  Microb Cell Fact       Date:  2011-06-29       Impact factor: 5.328

Review 5.  Daptomycin: a cyclic lipopeptide antimicrobial agent.

Authors:  LilyAnn Jeu; Horatio B Fung
Journal:  Clin Ther       Date:  2004-11       Impact factor: 3.393

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.